key: cord-0971949-pckrojdc
authors: Becker, Jonas; Stanifer, Megan Lynn; Leist, Sarah Rebecca; Stolp, Bettina; Maiakovska, Olena; West, Ande; Wiedtke, Ellen; Börner, Kathleen; Ghanem, Ali; Ambiel, Ina; Tse, Longping Victor; Fackler, Oliver Till; Baric, Ralph Steven; Boulant, Steeve; Grimm, Dirk
title: Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV-RNAi expression vectors
date: 2022-01-14
journal: Mol Ther
DOI: 10.1016/j.ymthe.2022.01.024
sha: f0c648d6050d9d2c220f4360892da674c7278a92
doc_id: 971949
cord_uid: pckrojdc

accines, clinically relevant modalities to curb the pandemic by directly attacking the virus on a genetic level remain highly desirable and urgently needed. Here, we comprehensively illustrate the capacity of Adeno-associated virus (AAV) vectors co-expressing a cocktail of three short hairpin (sh)RNAs (RNAi triggers) directed against the SARS-CoV-2 RdRp and N genes as versatile and effective antivirals. In cultured monkey cells and in human gut organoids, our most potent vector, called SAVIOR (SARS virus repressor), suppressed SARS-CoV-2 infection to background levels. Strikingly, in control experiments using single shRNAs, multiple SARS-CoV-2 escape mutants quickly emerged from infected cells within 24-48 hours. Importantly, such adverse viral adaptation was fully prevented with the triple-shRNA AAV vector even during long-term cultivation. In addition, AAV-SAVIOR efficiently purged SARS-CoV-2 in a new model of chronically infected human intestinal cells. Finally, intranasal AAV-SAVIOR delivery using an AAV9 capsid moderately diminished viral loads and/or alleviated disease symptoms in hACE2-transgenic or wild-type mice infected with human or mouse SARS-CoV-2 strains, respectively. Our combinatorial and customizable AAV/RNAi vector complements ongoing global efforts to control the COVID-19 pandemic and holds great potential for clinical translation as an original and flexible, preventive or therapeutic antiviral measure.

( Figure 1A ; shRNAs C1-C19). We focused on these two targets as the polymerase governs viral 140 genome replication, while the nucleocapsid protein is crucial for viral particle assembly and RNA 141 genome packaging. In addition, three shRNAs (C20-C22) were directed against the human 142 angiotensin-converting enzyme 2 (hACE2), i.e., the entry receptor for SARS-CoV-2. 34 We then 143 harnessed Vero E6 cells, which are highly susceptible to SARS-CoV-2 infection and express 144 hACE2, 35 to assess the efficacy of these 22 shRNAs. To this end, the shRNAs were expressed 145 from a U6 RNA polymerase III promoter, encoded in scAAV vectors (one shRNA per vector) and 146 packaged into the AAV-LK03 capsid, 36 which we had identified as a potent transducer in these 147 cells ( Figure S1 ). In this primary screen ( Figure 1B We also analyzed the integrity of the AAV vector constructs carrying multiple shRNA expression 200 cassettes, based on data that secondary shRNA structures can act as cryptic ITRs and trigger 201 packaging of truncated genomes. 44 While the latter were indeed observed ( Figure S4 ), we 202 detected ~65% full-length genomes in TRISPR-A or -C vector stocks, which we consider 203 reasonable. Still, future optimization of downstream manufacturing should aim at eliminating the 204 ~35% byproducts. 205

As noted, our rationale for creating a triple-shRNA vector included the concern that SARS-CoV-206 2 knockdown using single shRNAs may create a selection pressure forcing the evolution of escape 207 mutants that acquired resistance to the respective shRNA. This concern has previously also been 208 raised in the context of siRNA-or CRISPR/Cas13-based anti-SARS-CoV-2 strategies, 21,27,28 but, 209 to the best of our knowledge, has never been experimentally validated. Hence, we expected that 210 simultaneous targeting of three independent sites in the SARS-CoV-2 genome should prevent 211 viral escape. For experimental verification, we passaged SARS-CoV-2 in Vero E6 cells that were 212 pre-transduced with either a single shRNA vector (encoding C3, C8, C12 or control shRNAs) or 213 the multiplexed SAVIOR or TRISPR-C vectors ( Figure 3A ). As predicted, daily virus passaging 214 over a period of eight passages in the presence of the single C3 and C12 vectors consistently MZ153737.1, OD908225.1, MZ398586.1), none had mutations in all three sites targeted by the 242 SAVIOR construct. 243 Thereby, our results verify the aforementioned general concern, that RNAi-based antiviral 244 strategies can lead to the selection of escape mutants that have developed resistance against a 245 single RNAi trigger. Most importantly, our data show that targeting multiple sites in SARS-CoV-2 246 with different shRNAs from a combinatorial AAV vector prevents the generation or outgrowth of 247 such viral escape mutants, highlighting the translational potential of An alignment of 40,000 randomly selected full-length SARS-CoV-2 genomes illustrates that the 249 three shRNA target sites of SAVIOR do not lie within regions of major variability ( Figure 4C ). Here, 250

we performed this analysis retrospectively based on shRNAs that we had already selected at the 251 beginning of the pandemic, when fewer SARS-CoV-2 strains had been known. In the future, as 252 demonstrated by others, 23-26 such analysis can ideally be used to proactively identify optimal 253 shRNA target regions with maximum conservation across SARS-CoV-2 variants, thus facilitating 254 the development of broadly active, next-generation AAV-SAVIOR permutations. 255 256

Next, we asked whether AAV-shRNA-mediated knockdown could also provide a curative benefit 258 in cells that are already infected with SARS-CoV-2. When infecting the human colon carcinoma-259 derived cell line Caco-2 with SARS-CoV-2 at a high multiplicity of infection, we noticed that most 260 of the cells died within the first 48 h of infection while about 10% of them kept growing and dividing. 261

Interestingly, we found that these cells were also infected by SARS-CoV-2 and could be passaged 262 as a chronically infected cell clone that supported SARS-CoV-2 replication and secretion of de-263 novo infectious virus particles (data not shown). Transduction of these chronically infected human 264

intestinal Caco-2 cells with SAVIOR largely reduced both, virus replication in cells as monitored 265 by qRT-PCR against the SARS-CoV-2 genome ( Figure 5A ) and the number of infectious particles 266 released by the cells (Figure 5B ). At five days post-transduction with SAVIOR, SARS-CoV-2 replication was reduced to undetectable levels ( Figure 5A ) and only little amounts of de-novo 268 infectious virus particles were released by the originally chronically infected cells ( Figure 5B ). 269

Notably, in the TCID50 assay measuring SARS-CoV-2 progeny, the triple-shRNA vector 270 outperformed the best single-shRNA vector encoding the C8 shRNA at all time points ( Figure 5B ). 271

To study whether SAVIOR can actively interfere with SARS-CoV-2 infection in non-transformed 272 human cells, we used primary human ileum and colon epithelial cells, which are physiologically 273 relevant targets for SARS-CoV-2 infection. 45,46 These cells were grown as mini-gut organoids and 274 fully supported SARS-CoV-2 infection, replication and spread. 47 Pre-treatment of these mini-gut 275 organoids with SAVIOR or the single-shRNA C8 vector resulted in an almost complete prevention 276 of SARS-CoV-2 infection of primary human intestinal epithelial cells ( Figure 6A -B). 277

As a whole, our data demonstrate that AAV-SAVIOR does not solely act in a prophylactic 278 manner but can also be used after cell infection and actively cure infected cells. 279

In vivo modulation of SARS-CoV-2 replication and pathogenesis in two different mouse 281

To evaluate our vectors' ability to act as a prophylactic that mitigates wild-type SARS-CoV-2 283 infection and associated symptoms in vivo, we harnessed an established mouse model, i.e., K18-284 hACE-2 transgenic mice ( Figure 7A ). These mice were intranasally inoculated with 2x10 11 vector 285 genomes (vg) of AAV-SAVIOR or the TRISPR-C control vector packaged into the AAV9 capsid 286 before infection with 5x10 4 plaque-forming units (PFU) of wild-type SARS-CoV-2 seven days later 287 (n=4 mice per group). As additional controls, wild-type littermates were treated identically. Body 288 weight and disease score were monitored daily until the transgenic mice reached the maximum 289 disease score (Table S4 ) and qualified for euthanasia on day 5 or 6 post-infection. Lung and brain 290 tissue was collected, and from these, viral genomes and infectious titer (PFU) of SARS-CoV-2 291 were determined. 292

As expected, wild-type mice did not show any symptoms upon infection with SARS-CoV-2, 293 whereas hACE2-transgenic mice exhibited a decrease in body weight ( Figure 7B ) and an 294 increasing disease score (Figure 7C and Table S4), with similar values between mice treated with  295 SAVIOR and the TRISPR-C control vector. Importantly, at the time of euthanasia, we measured 296 a notable but not statistically significant trend towards a reduction of both, SARS-CoV-2 genome 297 copy numbers (17.4-fold) and infectious units (2.9-fold), in the lungs of hACE2-transgenic mice 298 treated with AAV-SAVIOR as compared to the TRISPR-C control ( Figure 7D ,F). As compared to 299 lung, SARS-CoV-2 copy numbers and infectious units were markedly higher in the brains of all 300 infected animals and were unaffected by treatment with AAV-SAVIOR, as expected from an 301 intranasal vector delivery ( Figure 7E ,G). Massive infection of the brain is a well-known 302 characteristic feature of this particular animal model and a major cause of morbidity upon SARS-303

CoV-2 infection. 48 Infection rates in the lungs and brains of wild-type control mice lacking hACE2 304 were below the detection limits of both assays, in line with the aforementioned lack of symptoms 305 in these animals. 306

We subsequently evaluated AAV-SAVIOR more extensively in a second murine challenge 307 model using wild-type BALB/c mice and the mouse-adapted SARS-CoV-2-MA10 strain, which 308 accurately reflects the lung disease phenotype seen in humans ( Figure 8A ). 49 The focus on this 309 alternative model based on a wild-type, immunocompetent strain provided several benefits, 310 especially the fact that we could more easily up-scale animal numbers as well as study and 311 compare young versus old mice, with the latter best reflecting human disease progression and 312 sequelae. Moreover, we used a five-fold lower dose of SARS-CoV-2 in these experiments, which 313 sufficed to establish a robust infection and may concurrently better approximate the conditions of 314 natural transmission among humans. Finally, unlike the K18-hACE2-transgenic model used 315

above, the MA10 model is not restricted by excessive SARS-CoV-2 infection of the brains of the 316 animals and the morbidity and mortality associated with this neuroinvasion.

Specifically, 10-weeks-old ("young") or one-year-old ("old") BALB/c mice were transduced 318 intranasally with 2×10 11 vg per mouse of AAV-SAVIOR (i.e., the same dose used before in the 319 K18-hACE-2 model), TRISPR-C or a second control encoding enhanced (E)GFP, all packaged in 320 AAV9 (n=5 mice per group). One or two weeks later, the animals were challenged with 1×10 4 PFU 321 of SARS-CoV-2-MA10. Body weight and airway resistance were monitored daily and lungs were 322 harvested at two or four days post-infection (dpi) for physiological, pathological and viral load 323 analysis ( Figure 8A ). 324

First, similar to the K18 model, we pre-treated young mice with AAV-SAVIOR, followed one 325

week later by SARS-CoV-2-MA10 infection. Notably, this yielded multiple lines of clear evidence 326 of a protective effect of our vectors, including the finding that treated mice were resistant to body 327 weight loss after challenge, a hallmark of protection in the pathogenic SARS-CoV-2-MA10 model 328 ( Figure 8B ). Furthermore, physiological indicators in AAV-SAVIOR-treated mice, including airway 329 obstruction and lung hemorrhage, showed non-significant improvements as compared to the 330 controls. These trends include a reduction of PenH and EF50 scores in SAVIOR-treated mice on 331 days 2 and 3, as well as a positive effect on hemorrhagic (HS) scores. While not reaching statistical 332 significance in the overall cohort, viral lung titers of individual mice treated with AAV-SAVIOR were 333 strongly reduced by up to 100-fold at 2 dpi (the peak titer of the MA10 model) ( Figure 8B ). At 4 334 dpi, we still observed a minor but noticeable trend towards reduction in lung titer ( Figure 8B ). 335

To study the longevity of AAV-SAVIOR-mediated protection against SARS-CoV-2 infection, we 336 next treated the mice two weeks before challenge, which is outside of the therapeutic windows of 337 the current biologic treatments, including nAbs, antiviral peptides and small molecule drugs. Under 338 these conditions, we observed no protective effect of AAV-SAVIOR as compared to the two 339 controls in terms of body weight loss or airway congestion scores ( Figure S6 ). Hemorrhagic scores 340 showed a significant reduction compared to the TRISPR-C but not the EGFP control. Although 341 there was no difference in lung viral titers at 2 dpi, a non-statistically significant reduction was observed at 4 dpi. Specifically, two out of five mice showed a 10-or 100-fold reduction in viral lung 343 titer, respectively, suggesting rapid viral clearance ( Figure S6 ). 344

To also assess the potential of AAV-SAVIOR in human populations that are less capable of 345 mounting robust immune responses following traditional vaccination, we used an aged mouse 346 model (1-year-old) that better reflects the physiology and disease progression of severe infection 347 in humans. When administered one week before SARS-CoV-2-MA10 challenge, AAV-SAVIOR 348 treatment reduced body weight loss compared to control treatments ( Figure 8C ). AAV-SAVIOR-349 treated mice also showed non-significant improvements in physiological markers including lung 350 hemorrhage and airway congestion scores at day 2 post-infection (HS and PenH) ( Figure 8C ). 351

This therapeutically relevant benefit was consistent with a significant reduction in lung viral titers 352 in AAV-SAVIOR-treated mice compared to both controls. The fact that this effect was noted at 353 four but not at two days post-infection ( Figure 8C ), i.e., the opposite of the results in young mice 354 ( Figure 8B ), suggests kinetic differences of AAV-SAVIOR in young versus old animals that warrant 355 further investigation. 356

To study whether shRNA multiplexing in AAV-SAVIOR could prevent the rise of SARS-CoV-2 357 escape variants also in vivo, we sequenced the regions of the viral genome targeted by the three 358 shRNAs (C3, C8 and C12) in this vector. This revealed the absence of any mutations in the 359 treatment or control groups (data not shown), and thus implies the ability of AAV-SAVIOR to 360 prevent the occurrence of spontaneous or shRNA-induced viral escape in vivo, congruent with 361 and extending our cell culture data ( Figure 4) . Still, additional work including more controls is 362 required to verify this conclusion also at later time points, which will be relevant for chronic SARS-363

CoV-2 infections in humans. 364

The outbreak of SARS-CoV-2 less than two years ago and its rapid escalation to a pandemic with 367 over 270 million global infections not only drastically illustrates the threat posed to humans by members of the Coronaviridae family, but it also highlights our deficits in understanding, 369 preventing or counteracting viral zoonosis and spread. Fortunately, a powerful arsenal of newly 370 emerging technologies has been established over the past decade in other contexts that can now 371 be repurposed at unparalleled speed. Particularly notable is vaccination technology based on 372 synthetic and formulated mRNA, which is already widely applied and which promises to slow or 373 even halt the pandemic in combination with other measures. Still, it is also becoming increasingly 374 clear that the ultimate goal of herd immunity may be difficult to reach for numerous reasons, 375

including the inherent propensity of SARS-CoV-2 to swiftly gain fitness and escape humoral 376 immunity via mutation, as drastically illustrated by the currently circulating and rapidly 377 disseminating Omicon strain. Other confounding factors are that a considerable percentage of the 378 human population opposes vaccination, that specific recipients such as lactating women or ailing 379 individuals may have to be excluded from vaccination, and that the latter may fail owing to a 380 suppressed or compromised immune system, or for other unknown reasons. Last but not least, 381 currently accumulating evidence implies that vaccine immunity wanes at different rates in the nose 382 and deep lung, hence even multiply-vaccinated individuals may eventually become susceptible 383 again to infection and virus transmission, further restricting chances of achieving herd immunity. 384

Together, these facts and concerns raise an urgent need to develop and preclinically validate 385 complementing, direct-acting antiviral strategies that promise full and long-lasting protection 386 and/or cure from SARS-CoV-2 infection, while overcoming the limitations of active vaccination 387 approaches and their restriction to a subset of the human population. As implied by the sum of ex 388 vivo and in vivo data reported here, the combinatorial AAV-SAVIOR vector may help to fill in this 389 gap and thereby complement other ongoing global efforts to curb the pandemic, based on a variety 390 of clinically pertinent benefits including efficacy, versatility and translatability. 391

A first important finding in this work was that several of our initially tested shRNAs mediated 392 robust inhibition of SARS-CoV-2 in cultured and infected cell lines or primary cells, akin to the gRNAs before. 21, [27] [28] [29] Further in line with data published in heterologous systems, we were not 395 surprised to note that our best vector, AAV-SAVIOR, yielded knockdown efficiencies that were 396 mostly similar to the single vector encoding our lead shRNA, C8. Identical findings were reported, 397 for instance, by Fareh et al. who found no differences between an N-targeted crRNA pool versus 398 their best individual crRNA, 28 or by Idris et al. who observed that combining their three most potent 399 siRNAs yielded the same SARS-CoV-2 knockdown efficiency as single siRNAs. 21 400

In all these cases including our own data, it is essential to note that multiplexing of RNAi or 401 CRISPR triggers primarily aims at attacking the virus at multiple sites and thus hampering its ability 402 to escape by mutation, rather than at improving overall efficiency. This propensity of pathogenic 403 viruses to rapidly develop resistance to a single inhibitor is a well-known and major concern in 404 antiviral RNAi and CRISPR strategies, especially for RNA viruses with error-prone replication such 405 as HIV, HCV or poliovirus. 40,42,50-52 Hence, we considered it crucial to provide experimental 406 evidence in this work that SARS-CoV-2 can indeed rapidly mutate and escape from a single 407 shRNA, as this concern has been raised multiple times before but, to our best knowledge, never 408 been verified to date. Strikingly, we found that the virus quickly escaped even from our most potent 409 shRNA when applied as a sole inhibitor, while it failed to do so under concurrent pressure from all 410 three shRNAs, in vitro and in vivo (Figure 3 and 4). These results are highly reminiscent of previous 411 findings for HIV and poliovirus, 50-52 and thus add SARS-CoV-2 to the list of pathogenic RNA 412 viruses for which combinatorial RNAi strategies are strictly indicated. 39 In this context, we note our 413 finding that of the three shRNAs tested in the passaging experiment, C8 resulted in escape in only 414 one out of three replicates, while mutational escape was observed in all three replicates with C12 415 and C3. This correlates well with the lower number of single-nucleotide variants observed in the 416 C8 target region as compared to the C12 and C3 targets among 365,255 SARS-CoV-2 isolates 417 that we assessed here (as of September 2021), including major variants of concern (Alpha 418 (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2)). In turn, this further highlights the 419 necessity to identify and target highly conserved sites in SARS-CoV-2 as well as illustrates the ensuing benefits for permanent in vivo control. Most importantly, all three target sites for the C3, 421 C8 and C12 shRNAs encoded in AAV-SAVIOR are also 100% conserved in the highly infectious 422

Omicron strain (B.1.1.529), which is currently rapidly replacing Delta in many parts of the world 423 and which seems largely resistant to the anti-SARS-CoV-2 immunity triggered by current vaccines. 424

As a whole, these notions are highly encouraging as they promise that future improved (see 425 below) iterations of AAV-SAVIOR may thwart viral mutational escape in the human population and 426 thus also enhance the efficacy of available vaccination regimes. The same concept is also pursued 427 by monoclonal antibody cocktails that target multiple epitopes to prevent escape mutants. 53 428

Further beneficial in this respect is the high versatility of our underlying AAV-TRISPR system, 429 which permits simple and fast assembly of concatemerized scAAV vectors encoding combinations 430 of up to three small RNAs via Golden Gate Assembly. Accordingly, unlike antibody therapeutics 431 or vaccines that require several months for development, AAV-SAVIOR provides a modular plug-432 and-play system with significantly shorter engineering time. Notably, these small RNAs can 433 comprise shRNAs as well as gRNAs, enabling combined expression of RNAi and CRISPR triggers 434 from a single AAV vector, and thereby offering the future ability to target and inhibit SARS-CoV-2 435 and its host cell factors on the RNA and DNA levels, respectively. As exemplified here, this can 436 include multiplexed targeting of three independent sites in the viral genome or transcripts, but one 437 can also envision concurrent inhibition of virus and host genes. The latter should further increase 438 the pressure on the virus and lower its chances to escape by mutation. Alternatively, it may also 439 be rewarding to co-express three shRNAs against the identical target site but covering distinct 440 point mutations, to prevent viral breakthrough at this site. These looming efforts will greatly benefit 441 from the multitude of algorithms and databases that are dedicated to the identification of optimal 442

RNAi and CRISPR targets in SARS-CoV-2 genomes, and which take numerous design 443 parameters into consideration including conservation, accessibility, off-targeting potential in the 444 host genome, and others. [23] [24] [25] [26] 28 Clinical translation of the vector reported here should further benefit from, and be accelerated 446 by, the long-standing experience in the field with its core components, namely, AAV capsids and 447

RNAi cargos. This includes one of the strengths of the AAV vector system that we harnessed here, 448

i.e., the ability to pseudotype cargos with a capsid mediating high and ideally specific transduction 449 of a target cell or organ. In this work, we used the LK03 capsid to transduce cultured Vero E6 cells 450 but then switched to AAV9 for transduction of mouse lungs in vivo. While this selection was 451 suggested by prior data showing the efficacy of this AAV isolate in the mouse lung, 54 it is clear 452 that another capsid, likely a genetically engineered version, 55 may be required to further improve 453 the AAV-SAVIOR system and to enable its translation into higher species including humans. In 454 this respect, we note exciting recent work by the Wilson lab, which identified two AAV variants 455 (hu68 and rh91) that potently transduced proximal airways in non-human primates when delivered 456 by a mucosal atomization device. 56 For the use of AAV-SAVIOR as a first-line-of-defense, it may 457 be beneficial to pseudotype the vector with these capsids and to then apply it as a spray to the 458 nose and upper airways, in order to block entry of SARS-CoV-2 into the body at an early step. 459

Moreover, using AAV barcoding and high-throughput in vivo screening technology, 57 we have 460 recently confirmed the ability of other AAV capsids, such as AAV4 or a peptide display variant of 461 AAV2, 58 to transduce the mouse lung from intravenous delivery. If translatable to humans, this 462 administration route could alleviate concerns in a therapeutic setting about physical barriers 463 imposed by the thick mucosa in the lungs of COVID-19 patients, or about SARS-CoV-2-containing 464 aerosols that may be caused by the use of nebulizers. However, intravenous AAV-SAVIOR 465 delivery would also increase its exposure to the host immune system and may limit its efficacy. 466

While these different possibilities require experimental validation, we are not concerned that 467 delivery of the vector reported here or of its descendants will become a bottleneck in the future, 468 considering the manifold solutions offered by the AAV engineering field. 55 469

Concurrent with the optimization of capsid and delivery route, it is prudent to also learn and 470 profit from the preclinical and clinical experience gathered with RNAi including in an AAV context.

In the past, AAV-RNAi vectors have been studied extensively as therapeutics for e.g. chronic liver 472 infection with hepatotropic viruses, including treatment of hepatitis C virus infection with a triple-473 shRNA construct (TT-033) in non-human primates. 40 In line with data in mice, 59 the same study 474 reported dose-dependent toxicity in transduced hepatocytes due to high shRNA expression levels 475 from RNA polymerase III promoters. Notably, subsequent promoter engineering to reduce shRNA 476 levels lowered toxicity and enabled a phase I clinical trial with the optimized vector TT-034 as a 477 first-in-human application of vector-delivered RNAi. 60 Therefore, future iterations of AAV-SAVIOR 478

intended for use in humans should likewise benefit from engineering and optimization of the 479 therapeutic cargo, including the identification of promoters for safest triple-shRNA expression. In 480 the context of persistent viral infections, we also note reports of chronic or recurrent infections with 481 SARS-CoV-2 in immunocompromised or immunodeficient patients. 61-63 While these may be 482 amenable to treatment with convalescent plasma 63 or antivirals such as Remdesivir, 64 they should 483 also benefit from a therapeutic application of AAV-SAVIOR, as supported by the robust viral 484 clearance that we observed here in chronically infected Caco-2 cells. To this end, it may be further 485 beneficial to include a genetic circuit in future vector generations, which senses the presence of 486 active or chronic viral replication or expression, and which thereby timely restricts vector activity. 487

Finally, as the viral stage is transient and followed by an immune reaction which can cause severe 488 pathology, it could be beneficial to additionally arm AAV-SAVIOR with an immunomodulatory 489 cargo or to supply this from a second vector, in order to extend the initially short window for direct 490 anti-viral targeting and to also control the detrimental host immune response at later stages. 491

Next to outlining a path for technical improvements, our results also raise a series of related 492 questions on the best parameters for clinical application including kinetics and doses, which we 493 could not address in this proof-of-concept study owing to the scarcity and inherent limitations of in 494 vivo SARS-CoV-2 models, but which should be tackled by follow-up work. In particular, it will be 495 seminal to more comprehensively characterize the in vivo persistence of triple-shRNA expression 496 at multiple time points and the shRNA activity following a single vector administration, to reveal the true potential of AAV-SAVIOR as a first-line-of-defense prophylactic. Along these lines, it will 498 also be interesting to measure virus titers at earlier time points, to identify beneficial effects that 499 may be overwritten at later endpoints owing to the high SARS-CoV-2 replication dynamics. 500

Within the aforementioned limits of in vivo studies on SARS-CoV-2, we acknowledge that the 501 prophylactic effects observed in the K18-hACE2 transgenic mice were moderate, probably due to 502 several reasons. One is that this mouse model requires a high virus input of 5x10 4 PFU to induce 503 pathogenesis in 100% of the animals, which is likely to overwhelm the antiviral capacity of our 504 vector. Secondly, this mouse model is further characterized by robust SARS-CoV-2 replication in 505 the brain and ensuing morbidity and mortality. While the AAV9 serotype is capable of crossing the 506 blood-brain barrier from an intravenous delivery in mice, 65 this was not expected in our study where 507 we used intranasal delivery. Accordingly, we observed no reduction in brain viral titers in the 508 treated K18-hACE2 mice. In contrast, the MA10 system provided more options for experimentation 509 and analysis, and also enbled the use of five-fold lower SARS-CoV-2 input doses. Consequently, 510

we could better investigate the prophylactic effect of AAV-SAVIOR by measuring viral loads at two 511 earlier timepoints (2 and 4 days post-infection), and we could also study two different age cohorts. 512

As shown, AAV-SAVIOR pre-treatment yielded a trend towards reduced SARS-CoV-2 infection 513 and related symptoms in both young and old mice. The best results comprised a protection from 514 weight loss in young mice and a significant reduction in lung viral titers in older animals. A likely 515 explanation for the stronger reduction of lung viral titers in older mice is the faster turnover rate of 516 airway epithelial cells in young versus old mice. 66 Typically, the turnaround rate of airway epithelial 517 cells is around six months in trachea and 17 months in lung, 67 but these periods can be shorter in 518 the case of injury. Importantly, in humans, this turnover rate is about 100 days to one year, or can 519 be even longer without injury, possibly providing a much wide(r) prophylactic window. 67,68 Still, we 520 also clearly recognize clinical benefit from alternative strategies such as fast and transient siRNA 521 delivery via nanoparticles, 21 especially in a therapeutic setting where long-term persistence of the advantages, including the fact that they may require only a single dose versus multiple for siRNA 524 or mRNA regimens. Moreover, as suggested by preclinical animal data, AAV capsid pseudotyping 525 permits retargeting to other infected sites in the human body, such as the brain 69 or the intestines, 70 526 which may be far more difficult to reach with peripherally delivered nanoparticles, naked siRNAs 527 or mRNA complexes. As indicated above, this should ultimately allow to target the AAV-SAVIOR 528 system specifically and efficiently to the main lung cells types that are infected by SARS-CoV-2 in 529 humans, i.e., alveolar type 2 (AT2) cells, 71,72 and thereby boost the vector's antiviral efficacy. 530

While the answers to these and other questions await further experimentation, this work already 531 illustrates the benefits of multiplexed shRNA expression from pseudotyped AAV vectors as a 532

prophylactic or therapeutic measure against SARS-CoV-2 infection and its clinical sequelae. While 533 multiple aspects of our first-generation AAV-SAVIOR vector can and will be improved, the current 534 iteration is sufficiently potent to inhibit viral replication and spread in cultured cells and in murine 535 lungs from a single administration. Furthermore, it thwarted viral escape in vitro and in vivo, which 536 we observed with traditional AAV vectors encoding a single shRNA and which represents a major 537 concern for any type of monotherapies. Combined with the general assets of AAV including 538 apathogenicity, stability at ambient temperature, clinical safety, advanced manufacturing 539 technology and ease of engineering, this implies that AAV-SAVIOR holds significant potential as 540 a new entry in our arsenal of measures to manage SARS-CoV-2 and other expected pandemics. 541

Design, cloning and multiplexing of anti-SARS-CoV-2 shRNAs. For the initial screening, 544 shRNAs were directed against the RdRP and N genes of SARS-CoV-2 (NC_045512.2; shRNAs 545 C1-19) or against the human ACE2 gene (NM_021804.3; shRNAs C20-22), and designed using 546 the "siRNA Wizard" (https://www.invivogen.com/sirnawizard/index.php). All shRNAs were first 547 cloned into single-shRNA vectors via Golden Gate Assembly (NEB, Ipswich, MA, USA). The 548 recipient scAAV vector genome contained two inverted BsmBI sites under a U6 promoter as well 549 as a GFP reporter controlled by a Rous Sarcoma Virus (RSV) promoter and a minimal 550 polyadenylation site. 59 Forward and reverse shRNA oligos (Table S1) Golden Gate Assembly was performed by cycling 25 times between 37°C for 2 min and 16°C for 557 3 min, and by finally inactivating the enzymes at 80°C for 10 min. Next, 5 µl of assembly mix were 558 used for heat shock transformation of chemically competent DH5α cells, which were spread onto 559 LB-agar plates containing 75 mg/L ampicillin. For selected clones, ITR integrity was assessed via 560

BsaI/XmaI control digestion, and correct insertion of shRNA oligos was validated via Sanger 561 sequencing (Eurofins Genomics, Ebersberg, Germany) using the primer U6-fw 5'-562 ACCGCTCGAGCGAGTCCAACACCCGTGG-3'. 563

To multiplex three shRNAs in a single scAAV-TRISPR vector, a two-step Golden Gate 564

Assembly protocol was applied as reported before. 43 In the first step, the selected oligos were 565 cloned into three different donor vectors containing either a U6, H1 or 7SK promoter via BsmBI-566 based Golden Gate Assembly as described above. After transformation of chemically competent 567 bacteria, the cells were recovered for 1 h in 1 ml LB medium (37°C, 800 rpm) and plated onto LB-568 agar plates containing 25 μg/ml chloramphenicol. Correct insertions were validated by Sanger 569 sequencing of selected clones using the M13Rev primer 5'-GGAAACAGCTATGACCATG-3'. The 570 TRISPR donor plasmids contain inverted BbsI sites flanking each promoter-shRNA cassette. In a 571 second Golden Gate Assembly step, these promoter-shRNA inserts were transferred to a recipient 572 scAAV construct containing an acceptor site for the shRNA cassettes and a truncated gfp as 573 stuffer. This yielded a final construct carrying the inserts U6-shRNA1 / H1-shRNA2 / 7SK-shRNA3 574 in a defined order. For this reaction, 20 fmol of recipient plasmid were mixed with 20 fmol of each donor plasmid (U6/H1/7SK), 1 µl T4 DNA ligase buffer (NEB), 0.5 µl T4 DNA ligase (400 U/μL, 576 NEB), 0.5 µl of BbsI (Thermo Scientific) and filled to 10 µl with H2O. Golden Gate Assembly cycling 577 was performed as described above, and transformed chemically competent bacteria were plated 578 on LB-agar plates with ampicillin. Sanger sequencing of selected clones was performed using the 579 U6-fw primer or the GFP-rev primer 5'-TCCTCCTTGAAGTCGATGC-3'. For the initial screens of the full shRNA panel in Vero E6 cells, vectors were produced in small 610 scale as "crude cell lysates" in 6-well format as reported before 76 using the LK03 capsid. 36 Briefly, 611 3x10 6 HEK293T cells were seeded in 6-well plates in 2 ml full medium. One day after seeding, 612 cells were transfected with 870 ng of each plasmid using a PEI mix containing 22 µl of PEI, 27 µL 613 H2O and 49 µl 300 mM NaCl (total volume 98 µl), which was then combined with the DNA mix 614 also in a total of 98 µl (DNA diluted in 49 µL H2O and 49 µl 300 mM NaCl). After vortexing and 615 incubating for 10 min at room temperature (RT), the combined mix was added dropwise to each 616 well. Forty-eight h post-transfection, medium was exchanged with 1 ml PBS (Life Technologies) 617 and cells were harvested by pipetting. After centrifuging at 1,500 g for 10 min, the cell pellet was 618 resuspended in 400 µl PBS and lysed by five freeze-thaw cycles (liquid nitrogen/37°C) and 1 min 619 sonication. Cell debris was removed by centrifuging the lysate for 10 min at 16,000 g and 620 discarding the pellet. 621

For subsequent experiments in cell culture, AAV production was scaled up to five 15 cm dishes 622 per construct using the LK03 capsid for transduction of Vero E6 cells and gut organoids, or AAV6 623 for transduction of Caco-2 cells. Therefore, 4x10 6 HEK293T cells were seeded per 15 cm plate 624 two days prior to triple-transfection. A DNA mix was prepared containing 74 µg of each plasmid 625 (shRNA vector, AAV helper and adenoviral helper) in 4 ml H2O and 4 ml 300 mM NaCl. Next, a combined, vortexed and incubated at RT for 10 min before being added dropwise to the cells. 628

Transfected cells were harvested 72 h later, pelleted by 15 min centrifugation at 800 g and 629 resuspended in 5 ml Benzonase buffer (150 mM NaCl, 50 mM Tris-HCl, 2 mM MgCl2; pH 8.5) 630 before being lysed with five consecutive freeze-thaw cycles (liquid nitrogen and water bath at 631 37°C). Lysates were incubated with 75 U/mL Benzonase (Merck, Darmstadt, Germany) for 1 h at 632 37°C, while inverting the tubes every 10 min. Cell debris was cleared by two rounds of 633 centrifugation at 4,000 g for 15 min and discarding the pellet. All vectors were purified via iodixanol 634 gradient density centrifugation. To this end, each lysate was filled to 7 ml and loaded to 635 ultracentrifugation tubes (Seton Scientific, Petulama, CA, USA) through a Pasteur pipette. This 636 was underlaid with 1.5 ml of each 15%, 25%, 40% and finally 60% iodixanol solution. Sealed tubes 637 were centrifuged at 50,000 rpm (4°C) for 2 h in a OptimaTM L-90K ultracentrifuge using the 70.1 638

Ti rotor (Beckman Coulter, Brea, CA, USA). Finally, the 40% iodixanol phase containing full 639 capsids was extracted through a needle, aliquoted and stored at -80°C. 640

For mouse experiments, the AAV9 capsid was used, and vectors were produced in 40 15 cm 641 dishes per construct. They were purified via iodixanol gradients as described above, but using 642 lysate from 20 plates per gradient tube, i.e., two gradients per sample. Each purified vector sample 643 (in 40% iodixanol) was then filled to 15 ml with PBS and concentrated to approx. 500 µl using 644 Amicon Ultra-15 centrifugation columns (Merck) by centrifugation at 1,000 g. Columns were briefly 645 inverted every 5 min to prevent clogging of the filter membrane. Evaluation of ACE2 knockdown with shRNA C20, C21 or C22 vectors. Single-shRNA AAV-673 LK03 vectors encoding shRNA ctrl, C20, C21 or C22 were produced, purified and titrated as 674 described before. Vero E6 cells were seeded in a 24-well format at a density of 1x10 5 cells per 675 well and immediately transduced at an MOI of 1x10 5 (one vector per well, n=3 wells per vector). 676

Three days later, cellular RNA was extracted using the RNeasy Mini Kit (QIAGEN) and converted 677 into cDNA using the High Capacity cDNA Synthesis Kit (Applied Biosystems). qRT-PCR of cDNA 678 was performed for ACE2 as well as the housekeeper GAPDH with the StepOnePlus Real-Time PCR System (Thermo Fisher) using the iTaq Universal SYBR Green Supermix (Bio-Rad). Primer 680 sets used for qRT-PCR were GAPDH_fw (5'-ACCCACTCCTCCACCTTTGAC-3') and 681

GAPDH_rev (5'-TGTTGCTGTAGCCAAATTCGTT-3') for GAPDH, and hACE2_fw (5'-682 TCCATTGGTCTTCTGTCACCCG-3') and hACE2_rev (5'-AGACCATCCACCTCCACTTCTC-3') 683 for ACE2. Each reaction was performed in duplicates, of which the mean Ct value was used for 684 further analysis. The difference in ACE2 expression was quantified by first normalizing ACE2 Ct 685 values to GAPDH for each replicate (i.e., ΔCt), and then normalizing the active shRNA (C20-C22) 686 conditions to shRNA ctrl (i.e., ΔΔCt). The fold-change in expression was finally calculated using 687 the 2 ΔΔCt method. Statistical significance was evaluated using a one-way ANOVA test. Germany) were coated with 2.5% human collagen in water for 1 h prior to organoids seeding. 723

Organoids were collected at a ratio of 100 organoids per well of a 48-well plate. Collected 724 organoids were spun at 450 g for 5 min and the supernatant was removed. Organoids were 725 washed with cold 1x PBS and spun at 450 g for 5 min. PBS was removed and organoids were 726 digested with 0.05% Trypsin-EDTA (Life Technologies) for 5 min at 37°C. Digestion was stopped 727 by addition of serum-containing medium. Organoids were spun at 450 g for 5 min and the 728 supernatant was removed, before organoids were re-suspended in normal growth media at a ratio 729 of 250 l media per well. The collagen mixture was removed from the ibidi chambers and 250 L replaced with differentiation media for four days. Following organoid differentiation, organoids 732 were transduced with AAV vectors at an MOI of 10 5 . Three days post-transduction, media was 733 removed and transduced organoids were infected with SARS-CoV-2 (BavPat1, passage 3) at an 734 inspected every day to assess disease score and body weight. Transgenic mice were harvested 824 when they qualified for euthanasia by reaching the maximum disease score of 20 (Table S4) . 825

Respective wild-type animals were always harvested in parallel. For organ harvest, mice were 826 deeply anesthetized with 5% isoflurane and killed by cervical dislocation, before lungs and brains 827 were collected, directly transferred into pre-cooled 2 ml homogenization tubes filled with 1.4 mm 828 ceramic beads (Omnilab, Bremen, Germany) and 500 µl DMEM without supplements. Tissue was 829 homogenized for one minute at 4 m/sec using a Bead Ruptor 12A (Omnilab), centrifuged at 4°C 830 for one minute at maximum speed, and supernatant was transferred into a fresh tube. 831

Samples for qPCR and plaque assay were generated from cleared organ homogenates. For 832 qPCR, 50 µl of cleared organ homogenate were mixed with 350 µl Lysis Buffer LBP (Macherey-RNA Plus Mini kit; Macherey-Nagel), cDNA synthesis (high-capacity cDNA reverse transcription 835 kit; Thermo Scientific) and RT-qPCR were performed as described previously. 73 performed by using SAMtools (v. 1.11) and BCFtools (v. 1.11). 81 Detected genomic variants were 877 annotated by SnpEff (v4.5.1) 82 using a locally built annotation database corresponding to the 878 NC_045512.2 reference acquired from the NCBI database as GFF (general feature format) file. 879

Computations were performed on a high-performance cluster running the Slurm Workload 880 Manager using 16 CPUs and 8 GB memory. Visualization of the genome-wide mutation landscape 881 was performed in R (version 3.6.3). 83 The dataset was split into 20 subsets and processed in 882 parallel due to computational limitations of R for character strings. Average identity (%) of 883 randomly picked 40,000 aligned full-length SARS-CoV-2 genomes per each genomic site was 884 calculated as the ratio of number of genomes with mutation to the total number of genomes in the dataset (40,000). Scripts used for variant calling, annotation and visualization are available from 886 the corresponding author upon request. 887

Statistical analysis. For quantification of P values, the GraphPad Prism software package was 889 used for conducting either a two-tailed unpaired t-test or the Kruskal-Wallis test with a Dunn's 890 multiple comparison test. P values are indicated with ns, for non-significant, *, p≤0.05; **, p≤0.01; 891 *** p≤0.001; ****, p≤0.0001. In Figure 7 , transgenic animals were compared among each other, 892 as were wild-type animals and animals that received the same treatment. Becker, Stanifer and co-workers report a novel, direct-acting strategy to suppress SARS-CoV-2 replication ex vivo and in vivo, which is based on a recombinant Adeno-associated viral (AAV) vector coexpressing three short hairpin (sh)RNAs against three different target regions in the SARS-CoV-2 genome that are conserved in multiple strains including Omicron.

Efficacy and Safety of the mRNA-922 1273 SARS-CoV-2 Vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-926 boost COVID-19 vaccine: an interim analysis of a randomised

BNT162b2 mRNA Covid-19 Vaccine

ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 934 randomised controlled trials in Brazil, South Africa, and the UK

Development of vaccines and antivirals for combating

Remdesivir for the 939 Treatment of Covid-19 -Final Report

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in 944 Outpatients with Covid-19

REGN-COV2, a Neutralizing Antibody Cocktail, in 947 Outpatients with Covid-19

Genomic Diversity and

Genomic and proteomic mutation 953 landscapes of SARS-CoV-2

Estimated 956 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Tracking Changes 960 in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to 965 humans

Spike mutation D614G alters SARS-CoV-968 2 fitness

SARS-CoV

V2 escapes neutralization by South African COVID-19 donor plasma

Prospective mapping of viral mutations that escape 975 antibodies used to treat COVID-19

Inhibition of 979 SARS-CoV replication by siRNA

Using siRNA in prophylactic and therapeutic regimens against 982 SARS coronavirus in Rhesus macaque

A SARS-CoV-2 targeted siRNA-985 nanoparticle therapy for COVID-19

A Small interfering RNA lead targeting RNA-dependent RNA-polymerase effectively inhibit the SARS-CoV-2 infection in Golden Syrian hamster and 989

A computational approach to design potential siRNA molecules as a 992 prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene 993 of SARS-CoV-2

A small interfering RNA (siRNA) database for SARS-CoV-2

Designing an effective therapeutic 999 siRNA to silence RdRp gene of SARS-CoV-2

Developing effective siRNAs to reduce the expression of 1001 key viral genes of COVID-19

Treatment of influenza and SARS

CoV-2 infections via mRNA-encoded Cas13a in rodents

Reprogrammed CRISPR-Cas13b suppresses

SARS-CoV-2 replication and circumvents its mutational escape through mismatch 1008 tolerance

Development of CRISPR as an Antiviral 1011 Strategy to Combat SARS-CoV-2 and Influenza

Adeno-associated virus vector as a platform 1015 for gene therapy delivery

Self-complementary 1017 recombinant adeno-associated virus (scAAV) vectors promote efficient transduction 1018 independently of DNA synthesis

Current Clinical 1021 Applications of Gene Therapy with AAVs

SARS-CoV-2 Cell Entry 1024 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Culture of SARS

CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile

Selection and evaluation of 1031 clinically relevant AAV variants in a xenograft liver model

A Scalable and Accurate Method for 1033

Quantifying Vector Genomes of Recombinant Adeno-Associated Viruses in Crude Lysate

Pre-arrayed Pan-AAV Peptide

Display Libraries for Rapid Single-Round Screening

Combinatorial RNAi: a winning strategy for the race 40

HIV develops indirect cross-resistance 1044 to combinatorial RNAi targeting two distinct and spatially distant sites

Single-cut genome editing 1050 restores dystrophin expression in a new mouse model of muscular dystrophy

Short DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome 1054

Detection of 1056 SARS-CoV-2 in Different Types of Clinical Specimens

Gastrointestinal Infection of SARS-CoV-2. Gastroenterology

Critical Role 1061 of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial 1062

A Mouse-Adapted SARS-CoV

Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

Human 1071 immunodeficiency virus type 1 escape from RNA interference

Short Interfering RNA-Target Recognition and Implications for Therapeutic Approaches

with RNA interference: a multiple shRNA approach

Antibody cocktail to SARS-CoV-2 spike protein 1079 prevents rapid mutational escape seen with individual antibodies

The AAV9 receptor and its modification 1083 to improve in vivo lung gene transfer in mice

E Pluribus Unum: 50 Years of Research

Viruses, and One Goal--Tailored Acceleration of AAV Evolution

Herrmann, 1090 by massively parallel in vivo evaluation of barcoded capsid variants

Pulmonary Targeting of Adeno-1095 associated Viral Vectors by Next-generation Sequencing-guided Screening of Random 1096

Fatality in mice due to oversaturation of cellular 1099 microRNA/short hairpin RNA pathways

258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi)

Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic 1103

Chronic SARS-CoV-2

COVID-19 Sequelae

Treatment of chronic or 1108 relapsing COVID-19 in immunodeficiency

SARS-CoV-2 evolution during 1112 treatment of chronic infection

Analysis of AAV 1118 serotypes 1-9 mediated gene expression and tropism in mice after systemic injection

Proliferation of respiratory tract epithelium in the rat

Ciliated epithelial cell lifespan in the mouse trachea 1123 and lung

Engineered AAVs 1128 for efficient noninvasive gene delivery to the central and peripheral nervous systems

Identification of adeno-1132 associated viral vectors suitable for intestinal gene delivery and modulation of 1133 experimental colitis

SARS-CoV-2 Reverse Genetics 1136 Reveals a Variable Infection Gradient in the Respiratory Tract

SARS-CoV replicates in primary 1139 human alveolar type II cell cultures but not in type I-like cells

CoV-2-Induced Reshaping of Subcellular Morphologies

Human Intestinal Organoids Maintain Self-Renewal Capacity

Cellular Diversity in Niche-Inspired Culture Condition

Adeno-associated virus vectors can be efficiently produced 1149 without helper virus

Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein 1153

Stability in Mammalian and Insect Cells

A Robust and All-Inclusive Pipeline for 1156 Shuffling of Adeno-Associated Viruses

SARS-CoV-2 1159 structure and replication characterized by in situ cryo-electron tomography

Evaluating Viral Respiratory Pathogenesis

Fast and accurate short read alignment with Burrows-1164

A program for annotating and predicting the effects of single 1170 nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain 1171 w1118

R: A language and environment for statistical computing. R 1173 Foundation for Statistical Computing

antibody staining normalized to non-transduced cells, (E) fold-change of SARS-CoV-2 genome 1194 copy numbers by qPCR as compared to input, and (F) titers of infectious virus by TCID50 assay

Multiplexing of shRNA lead candidates in the AAV-TRISPR format 1197 (A) Configurations of AAV-TRISPR vectors containing three expression cassettes in which the U6, 1198 H1 and 7SK promoters drive expression of the anti-SARS-CoV-2 shRNAs C3, C8 and C12 in 1199 various permutations including a non-targeting control shRNA (ctrl)

CoV-2 infection of Vero E6 cells with the indirect immunofluorescence assay normalized to non-1201 transduced cells (-AAV; set to 100%). Cells were pretreated with vector lineages derived from (B)

TRISPR-A (shRNA C8 in position 1 under the U6 promoter) or (C) TRISPR-B (shRNA C3 in 1203 position 1 under the U6 promoter

Scheme of all vectors used in this experiment. (B) Results from passaging of SARS-CoV-2 1207 every 24 h on Vero E6 cells transduced with single shRNA vectors (shRNA ctrl, C3, C8 or C12), 1208 or with AAV-SAVIOR or the corresponding TRISPR-C control vector. Percentages of infected cells 1209 were measured for each passage and normalized to

Representative original images of the indirect immunofluorescence assay used to calculate the 1211 data in panel (B)

occurrences within C3, C8 and C12 shRNA binding sites revealed from variant-calling analysis of 1220 365,255 full-length SARS-CoV-2 genomes. (C) Average identity (%) of randomly selected 40,000 1221 full-length SARS-CoV-2 genomes with positions of C8

C12) or N (C3)

A-B) Transduction of Caco-2 cells chronically infected with SARS-CoV-2 with single shRNA 1226 vectors encoding C8 or control shRNA, or with AAV-SAVIOR or the corresponding TRISPR-C 1227 control. Additional controls were mock-infected or non-transduced (-AAV) Caco-2 cells. (A) Fold-1228 change of SARS-CoV-2 genome copy numbers relative to virus input as measured by qPCR at 2, 1229 3 or 5 days post-infection. (B) Quantification of infectious SARS-CoV-2 particles 2

Body weight relative to day 0 post-infection. The dashed grey line indicates 1247 initial body weight (100%). (C) Disease score according to the score sheet. The dashed grey line 1248 indicates score at which animals became eligible for euthanasia. Shown are mean values ± SD 1249 from four (0-5 days post-infection (dpi); two mice were harvested at day 5) or two (6 dpi) mice per 1250 time point

The dashed red line indicates the limit of detection (LoD) of the assays, which is 1,810 genome 1253 copies per ml for the N1 gene qPCR, and 0 plaques/ml for the plaque assay